APA (7th ed.) Citation

James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., . . . Parmar, M. K. B. (2016). Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet (British edition), 387(10024), 1163-1177. https://doi.org/10.1016/S0140-6736(15)01037-5

Chicago Style (17th ed.) Citation

James, Nicholas D., et al. "Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial." The Lancet (British Edition) 387, no. 10024 (2016): 1163-1177. https://doi.org/10.1016/S0140-6736(15)01037-5.

MLA (9th ed.) Citation

James, Nicholas D., et al. "Addition of Docetaxel, Zoledronic Acid, or Both to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Survival Results from an Adaptive, Multiarm, Multistage, Platform Randomised Controlled Trial." The Lancet (British Edition), vol. 387, no. 10024, 2016, pp. 1163-1177, https://doi.org/10.1016/S0140-6736(15)01037-5.